Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice

作者：Xingguo Hou, Song Liu, Ziqing Zeng, Zilei Wang, Jin Ding, Yan Chen, Xiangyu Gao, Jianghua Wang, Guanxi Xiao, Baiyong Li, Hua Zhu, Zhi Gang Yang · 发表于：Biomedicine & Pharmacotherapy · 年份：2024 · DOI：10.1016/j.biopha.2024.116669 · 被引用次数：15 · 研究领域：Cancer Immunotherapy and Biomarkers、Radiopharmaceutical Chemistry and Applications、Monoclonal and Polyclonal Antibodies Research

BACKGROUND: The lack of an efficient way to screen patients who are responsive to immunotherapy challenges PD1/CTLA4-targeting cancer treatment. Immunotherapeutic efficacy cannot be clearly determined by peripheral blood analyses, tissue gene markers or CT/MR value. Here, we used a radionuclide and imaging techniques to investigate the novel dual targeted antibody cadonilimab (AK104) in PD1/CTLA4-positive cells in vivo. METHODS: tumor-infiltrating T cells and monitor their distribution in mice to evaluate the therapeutic effect. RESULTS: I-AK104 imaging had excellent standard uptake values at the tumor site and higher tumor to nontumor (T/NT) ratios. CONCLUSIONS: I-AK104 into a method for screening patients who benefit from immunotherapy and the efficacy, as well as the feasibility, of this method was verified by immuno-PET imaging of humanized mice.